文献速递免疫规划传染病防控与疫情报告

黏膜COVID-19疫苗的前景与挑战

Promises and challenges of mucosal COVID-19 vaccines.
PubMed 文献 · Vaccine · 2023-04-10

COVID-19疫苗目前采用肌内注射,能引发高效预防重症和死亡的系统性免疫应答,但疫苗诱导的免疫在短时间内减弱,目前建议接种加强针;现有疫苗配方不能充分限制鼻咽部等黏膜部位的病毒感染,阻断传播能力有限。多种黏膜疫苗正在开发中,旨在在SARS-CoV-2感染起始的黏膜部位诱导持久保护性免疫应答。本文讨论黏膜部位触发的免疫应答、SARS-CoV-2感染和当前COVID-19疫苗诱导黏膜应答的认识进展,并重点介绍正在开发或测试供人使用的几种黏膜SARS-CoV-2疫苗配方及黏膜接种的潜在挑战。

要点

  • 肌内注射COVID-19疫苗能高效预防重症和死亡,但免疫短时间内减弱,目前建议加强针。
  • 现有疫苗配方不能充分限制鼻咽部等黏膜部位的病毒感染,阻断传播能力有限。
  • 多种黏膜SARS-CoV-2疫苗正在开发或测试供人使用,旨在黏膜部位诱导持久保护性免疫应答。

核心结论

  • 黏膜疫苗开发旨在在SARS-CoV-2感染起始的黏膜部位诱导持久保护性免疫应答,过往黏膜接种的成功经验凸显这些处于开发阶段的SARS-CoV-2疫苗降低疾病负担的潜力。

研究设计与样本

  • 本文为综述,讨论黏膜部位触发的免疫应答、SARS-CoV-2感染和当前COVID-19疫苗诱导黏膜应答的认识进展,并重点介绍正在开发或测试供人使用的几种黏膜SARS-CoV-2疫苗配方及黏膜接种的潜在挑战。

主要发现

  • 当前COVID-19疫苗采用肌内注射,能引发高效预防重症和死亡的系统性免疫应答。
  • 疫苗诱导的免疫在短时间内减弱,目前建议接种加强针。
  • 当前疫苗配方不能充分限制鼻咽部等黏膜部位的病毒感染,阻断病毒传播的能力有限。
  • 多种黏膜疫苗正在开发中,旨在在SARS-CoV-2感染起始的黏膜部位诱导持久保护性免疫应答。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coronavirus disease-2019 (COVID-19) is an ongoing pandemic caused by the newly emerged virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, COVID-19 vaccines are given intramuscularly and they have been shown to evoke systemic immune responses that are highly efficacious towards preventing severe disease and death. However, vaccine-induced immunity wanes within a short time, and booster doses are currently recommended. Furthermore, current vaccine formulations do not adequately restrict virus infection at the mucosal sites, such as in the nasopharyngeal tract and, therefore, have limited capacity to block virus transmission. With these challenges in mind, several mucosal vaccines are currently being developed with the aim of inducing long-lasting protective immune responses at the mucosal sites where SARS-COV-2 infection begins. Past successes in mucosal vaccinations underscore the potential of these developmental stage SARS-CoV-2 vaccines to reduce disease burden, if not eliminate it altogether. Here, we discuss immune responses that are triggered at the mucosal sites and recent advances in our understanding of mucosal responses induced by SARS-CoV-2 infection and current COVID-19 vaccines. We also highlight several mucosal SARS-COV-2 vaccine formulations that are currently being developed or tested for human use and discuss potential challenges to mucosal vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rathore APS, St John AL. Promises and challenges of mucosal COVID-19 vaccines. Vaccine. 2023. PMID: 37045682. doi:10.1016/j.vaccine.2023.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。